跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
English
中文
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
設備
獎項
活動
新聞/媒體
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
楊 展庚
臨床助理教授
,
醫學系
電子郵件
D000019779
cgu.edu
tw
h-index
h10-index
h5-index
132
引文
8
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
132
引文
8
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
110
引文
7
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2015
2024
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(1)
研究產出
(16)
相近領域學者
(6)
指紋
查看啟用 Chan-Keng Yang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Patient
100%
Survival
57%
Cells
54%
Inpatient
53%
T Cell
52%
Nodular Melanoma
51%
Neoplasm
48%
Combination Therapy
43%
Therapeutic Procedure
43%
Overall Survival
37%
Immune Checkpoint Inhibitor
33%
Differentiation
32%
Association
30%
Tumor Microenvironment
30%
Experience
28%
Antibody
28%
Analysis
28%
Prognostic Factor
26%
Human Leukocyte Antigen
25%
Liver
25%
Metastatic Colorectal Cancer
25%
Treatment Response
25%
Chronic Hepatitis C
25%
Maturation
25%
Liver Failure
25%
Cell Aggregation
25%
Myeloid Cell
25%
Cancer of Unknown Primary Origin
25%
Myeloid-Derived Suppressor Cell
25%
T-Helper Cell
25%
Inducible Nitric Oxide Synthase
25%
Paracetamol
25%
Hepatocellular Carcinoma
25%
Growth
25%
Breast Cancer
25%
Cohort Analysis
25%
Acute Heart Infarction
25%
Standardized Uptake Value
25%
Lymph Node
25%
Esophageal Cancer
25%
Primary Tumor
25%
Tumor Progression
21%
Liver Tumor
20%
Cell Expansion
20%
Tumor Model
20%
CpG Oligodeoxynucleotide
20%
Monitoring
20%
Hazard Ratio
20%
Progression Free Survival
19%
Ex Vivo
17%
Immunology and Microbiology
Liver
58%
Cytotoxic T-Cell
53%
Cells
45%
Growth
29%
Molecule
28%
Monospecific Antibody
28%
Immunity
27%
Cluster of Differentiation
25%
Maturation
25%
Human Leukocyte Antigen
25%
Hepatitis C
25%
Myeloid-Derived Suppressor Cell
25%
CD4
25%
Cell Aggregation
25%
Myeloid
25%
Antineoplastic Activity
25%
Association
25%
Survival
25%
T Cell
23%
Aptitude
18%
Cytokine
17%
Cell Expansion
17%
CpG Oligodeoxynucleotide
17%
Mouse
12%
Phenotype
10%
Overall Survival
9%
Progression Free Survival
9%
Viral Hepatitis
8%
TLR9
8%
Neutrophil Granulocyte
7%
T Cell Receptor
7%
Tumor Necrosis Factor Alpha
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antiemetic Agent
25%
Cisplatin
25%
Metastatic Colorectal Cancer
25%
Acute Heart Infarction
25%
Colon Cancer
25%
Chemotherapy
25%
Palonosetron
25%
Melanoma
25%
Aprepitant
25%
Dexamethasone
25%
Cancer Risk
25%
Epidermolysis
25%
Diseases
14%
Overall Survival
14%
Neoplasm
13%
Malignant Neoplasm
11%
HLA B51 Antigen
11%
Progression Free Survival
9%
Adverse Event
7%
Combination Drug
6%
Liver Metastasis
6%
Pembrolizumab
6%
Nivolumab
6%
Recurrent Disease
5%
Carcinoembryonic Antigen
5%
RNA-Sequencing
5%
